Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Leads Biolabs Co (FRA:0DX) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Nanjing Leads Biolabs Co Effective Interest Rate on Debt % Related Terms
Nanjing Leads Biolabs Co Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Leads Biolabs Co Effective Interest Rate on Debt % Chart
Nanjing Leads Biolabs Co Annual Data
Trend
Dec23
Dec24
Dec25
Effective Interest Rate on Debt %
2.09
3.47
2.53
Nanjing Leads Biolabs Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Effective Interest Rate on Debt %
0.00
7.13
2.52
2.47
2.46
FRA:0DX vs VRTX, REGN, RVMD: Effective Interest Rate on Debt % Comparison
For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Leads Biolabs Co Effective Interest Rate on Debt % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is two times the semi-annual (Dec. 2025) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 2.46% mean?
Nanjing Leads Biolabs Co (FRA:0DX) has a Effective Interest Rate on Debt % of 2.46% as of Dec. 2025. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Nanjing Leads Biolabs Co and its competitors.
Is Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % too high?
Nanjing Leads Biolabs Co's current Effective Interest Rate on Debt % is 2.46%. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % compare to VRTX and REGN?
Nanjing Leads Biolabs Co's Effective Interest Rate on Debt % of 2.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Effective Interest Rate on Debt % is 2.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (FRA:0DX) has a current Effective Interest Rate on Debt % of 2.46%. The current Effective Interest Rate on Debt % is 2.46%. Nanjing Leads Biolabs Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (FRA:0DX), the current Effective Interest Rate on Debt % is 2.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
19GF Score
Get the complete analysis for FRA:0DX
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0DX has been successfully added to your 
